Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 4 Years in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. J of Skin [Internet]. 2024 Jul. 23 [cited 2026 Apr. 20];8(4):s407. Available from: https://skin.dermsquared.com/skin/article/view/2856